Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Roche’s Tecentriq yields positive data in early stage NSCLC

Roche’s Tecentriq yields positive data in early stage NSCLC the dominant shadow of Merck &Co’s Keytruda (pembrolizumab). ... Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC.

NICE rejects Keytruda for advanced bladder cancer in final guidance

NICE rejects Keytruda for advanced bladder cancer in final guidance Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although

FDA advisory committee to review oncology accelerated approvals

FDA advisory committee to review oncology accelerated approvals trials. However, continued approval in this indication was dependent on a post-marketing study demonstrating the superiority of Keytruda as determined by overall survival (OS). ... Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as

Novartis’ canakinumab misses the mark in previously treated NSCLC

Novartis’ canakinumab misses the mark in previously treated NSCLC The CANOPY-1 study, evaluating canakinumab in combination with Merck &Co’s Keytruda (pembrolizumab) and chemotherapy in previously untreated NSCLC patients, could report final results before the end of the year.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...